Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation
Bejanyan, Nelli (University of Minnesota)
Zhang, Mei-Jie (Medical College of Wisconsin)
Wang, Hai-Lin (Medical College of Wisconsin)
Lazaryan, Aleksandr (University of Minnesota)
de Lima, Marcos (University Hospitals Case Medical Center)
Marks, David I. (University Hospitals Bristol NHS Trust)
Sandmaier, Brenda M. (Fred Hutchinson Cancer Research Center)
Bachanova, Veronika (University of Minnesota)
Rowe, Jacob (Shaare Zedek Medical Center (Jerusalem, Israel))
Tallman, Martin (Memorial Sloan Kettering Cancer Center)
Kebriaei, Partow (The University of Texas MD Anderson Cancer Center)
Kharfan-Dabaja, Mohamed (H. Lee Moffitt Cancer Center and Research Institute)
Peter Gale, Robert (Imperial College London)
Lazarus, Hillard M. (University Hospitals Cleveland Medical Center)
Ustun, Celalettin (University of Minnesota)
Copelan, Edward (Carolinas HealthCare System)
Ky Hamilton, Betty (Cleveland Clinic Taussig Cancer Institute)
Schiller, Gary (David Geffen School of Medicine at UCLA (Los Angeles, Estats Units d'Amèrica))
Hogan, Willian (Mayo Clinic (Rochester, Estats Units d'Amèrica))
Hashmi, Shahrukh (King Faisal Specialist Hospital and Research Centre (Aràbia Saudita))
Seftel, Matthew (CancerCare Manitoba)
Kanakry, Christopher G. (National Institutes of Health (Bethesda, Estats Units d'Amèrica))
Olsson, Richard F. (Uppsala University)
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau)
Saber, Wael (Medical College of Wisconsin)
Khoury, H.Jean (Emory University Hospital)
Weisdorf, Daniel J. (University of Minnesota)
Universitat Autònoma de Barcelona

Data:	2018
Resum:	Allogeneic hematopoietic cell transplantation (alloHCT) is curative for patients with acute lymphoblastic leukemia (ALL) who achieve complete remission (CR1) with chemotherapy. However, the benefit of consolidation chemotherapy remains uncertain in patients undergoing alloHCT. We compared clinical outcomes of 524 adult patients with ALL in CR1 who received ≥2 (n = 109), 1 (n = 93), or 0 cycles (n = 322) of consolidation before myeloablative alloHCT from 2008 to 2012. As expected, time to alloHCT was longer with increasing cycles of consolidation. Patients receiving ≥2, 1, or 0 cycles of consolidation had an adjusted 3-year cumulative incidence of relapse of 20%, 27%, and 22%; 1-year transplant-related mortality (TRM) of 16%, 18%, and 23%; adjusted 3-year leukemia-free survival (LFS) of 54%, 48%, and 47%; and 3-year overall survival (OS) of 63%, 59%, and 54% (all P values.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	ALL ; Allogeneic transplant ; Consolidation chemotherapy ; Myeloablative conditioning
Publicat a:	Biology of blood and marrow transplantation, Vol. 24 Núm. 5 (may 2018) , p. 945-955, ISSN 1523-6536

DOI: 10.1016/j.bbmt.2017.12.784
PMID: 29275139

11 p, 547.4 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats